Author

Benjamin Ory

Observed names: B. Ory, BENJAMIN ORY, Ben Ory, Benjamin ORY, ORY, Benjamin, Ory B, Ory Benjamin, Ory, B., Ory, Benjamin

Institutions: Centre National de la Recherche Scientifique, Inserm, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers, Université de Nantes, Université d'Angers, Nantes Université

Observed institutions: Centre National de la Recherche Scientifique, Harvard University, Inserm, University of Eastern Finland, Université Nantes Angers Le Mans, Centre Hospitalier Universitaire de Nantes, Massachusetts General Hospital, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers, La Ligue Contre le Cancer, Cancéropôle Grand Ouest, Université de Nantes, Université d'Angers, University of Turin, Nantes Université

ORCID: 0000-0002-2622-7356

Observed ORCID: 0000-0002-2622-7356

OpenAlex ID: A5086139671

Sarcoma treatment in the era of molecular medicine

2020 · Thomas GP Grünewald, Marta Alonso, et al. · EMBO Molecular Medicine · 319

Circulating Tumor Cells: A Review of Non–EpCAM-Based Approaches for Cell Enrichment and Isolation

2016 · Marta Tellez Gabriel, Lidia Rodriguez Calleja, et al. · Clinical Chemistry · 238

Tumour Heterogeneity: The Key Advantages of Single-Cell Analysis

2016 · Marta Tellez-Gabriel, Benjamin Ory, et al. · International Journal of Molecular Sciences · 196

PDF

Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma‐bearing mice

2005 · Benjamin Ory, Marie‐Françoise Heymann, et al. · Cancer · 169

PDF

Identification of genomic differences among peripheral arterial beds in atherosclerotic and healthy arteries

2018 · Marja Steenman, Olivier Espitia, et al. · Scientific Reports · 167

PDF

Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle

2014 · François Lamoureux, Marc Baud’huin, et al. · Nature Communications · 147

PDF

Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma

2005 · D. Heymann, B. Ory, et al. · Bone · 142

Mechanisms of Resistance to Conventional Therapies for Osteosarcoma

2021 · Louise Marchandet, Morgane Lallier, et al. · Cancers · 138

PDF

Bisphosphonates: new therapeutic agents for the treatment of bone tumors

2004 · Dominique Heymann, Benjamin Ory, et al. · Trends in Molecular Medicine · 136

FGFR2 signaling underlies p63 oncogenic function in squamous cell carcinoma

2013 · Matthew R. Ramsey, Catherine Wilson, et al. · Journal of Clinical Investigation · 114

MicroRNA‐17‐5p Reduces Inflammation and Bone Erosions in Mice With Collagen‐Induced Arthritis and Directly Targets the JAK/STAT Pathway in Rheumatoid Arthritis Fibroblast‐like Synoviocytes

2020 · Aurélie Najm, François‐Marie Masson, et al. · Arthritis & Rheumatology · 108

PDF

Physical Association of HDAC1 and HDAC2 with p63 Mediates Transcriptional Repression and Tumor Maintenance in Squamous Cell Carcinoma

2011 · Matthew R. Ramsey, Lei He, et al. · Cancer Research · 107

PDF

Zoledronic Acid Activates the DNA S-Phase Checkpoint and Induces Osteosarcoma Cell Death Characterized by Apoptosis-Inducing Factor and Endonuclease-G Translocation Independently of p53 and Retinoblastoma Status

2006 · B. Ory, F. Blanchard, et al. · Molecular Pharmacology · 99

Zoledronic Acid Potentiates mTOR Inhibition and Abolishes the Resistance of Osteosarcoma Cells to RAD001 (Everolimus): Pivotal Role of the Prenylation Process

2010 · Gatien Moriceau, Benjamin Ory, et al. · Cancer Research · 97

Cytosine methylation of mature microRNAs inhibits their functions and is associated with poor prognosis in glioblastoma multiforme

2020 · Mathilde Cheray, Amandine Etcheverry, et al. · Molecular Cancer · 92

PDF

Origin and Therapies of Osteosarcoma

2022 · Brice Moukengue, Morgane Lallier, et al. · Cancers · 83

PDF

BYL719, a new α‐specific PI3K inhibitor: Single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma

2014 · Bérengère Gobin, Marc Baud' Huin, et al. · International Journal of Cancer · 78

PDF

A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma

2011 · Benjamin Ory, Matthew R. Ramsey, et al. · Journal of Clinical Investigation · 75

PDF

NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate

2013 · Bérengère Gobin, Séverine Battaglia, et al. · Cancer Letters · 70

PDF

Inhibition of BET proteins and epigenetic signaling as a potential treatment for osteoporosis

2016 · Marc Baud'huin, François Lamoureux, et al. · Bone · 61

ΔNp63α Silences a miRNA Program to Aberrantly Initiate a Wound-Healing Program That Promotes TGFβ-Induced Metastasis

2016 · Lidia Rodriguez Calleja, Camille Jacques, et al. · Cancer Research · 50

Targeting the epigenetic readers in Ewing Sarcoma inhibits the oncogenic transcription factor EWS/Fli1

2016 · Camille Jacques, François Lamoureux, et al. · Oncotarget · 49

PDF

Imatinib Mesylate Exerts Anti-Proliferative Effects on Osteosarcoma Cells and Inhibits the Tumour Growth in Immunocompetent Murine Models

2014 · Bérengère Gobin, Gatien Moriceau, et al. · PLoS ONE · 49

PDF

Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival

2006 · François Gouin, Benjamin Ory, et al. · International Journal of Cancer · 48

PDF

Feedback Control of p53 Translation by REDD1 and mTORC1 Limits the p53-Dependent DNA Damage Response

2011 · Douangsone D. Vadysirisack, Franziska Baenke, et al. · Molecular and Cellular Biology · 47

Works count: 166

Citation count: 3,748

H-index: 36

I10-index: 54